Abbott Laboratories Limited

Abbott House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, SL6 4XE, UK
Telephone: +44 (0)1628 773 355
Fax: +44 (0)1628 644 185
WWW: http://www.abbottuk.com
Medical Information Direct Line: +44 (0)1628 774 920
Medical Information e-mail: ukmedinfo@abbott.com

Summary of Product Characteristics last updated on the eMC: 04/10/2010
SPC Duodopa intestinal gel

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 04/10/2010 and displayed until Current
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
Date of revision of text on the SPC:   01-Oct-2010
Legal Category:   POM
Black Triangle (CHM):   YES

Free-text change information supplied by the pharmaceutical company



Section 7:

 

From:

 

Solvay Pharmaceuticals GmbH

Hans-Boeckler-Allee 20

D-30173 Hannover

Germany

 

To:

 

Abbott Products GmbH

Hans-Boeckler-Allee 20

D-30173 Hannover

Germany

Updated on 08/09/2010 and displayed until 04/10/2010
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 5.3 - Preclinical Safety Data
Date of revision of text on the SPC:   20-Aug-2010
Legal Category:   POM
Black Triangle (CHM):   YES

Free-text change information supplied by the pharmaceutical company



Section 4.2

 

From:

 

Morning bolus dose: 140 mg = 7 ml (including the volume to fill the intestinal tube)

 

To:

 

Morning bolus dose: 140 mg = 7 ml (excluding the volume to fill the intestinal tube)

 

 

Section 4.4

 

The following statement has been included;

 

Duodopa contains hydrazine, a degradation product of carbidopa that can be genotoxic and possibly carcinogenic. The average recommended daily dose of Duodopa is 100 ml, containing 2 g levodopa and 0.5 g carbidopa. The maximum recommended daily dose is 200 ml. This includes hydrazine at up to an average exposure of 4 mg/day, with a maximum of 8 mg/day. The clinical significance of this hydrazine exposure is not known.

 

 

Section 4.8

 

The frequency sub headings have been updated.

 

 

Section 5.3

 

The following statement has been included;

 

Hydrazine is a degradation product of Carbidopa. In animal studies, hydrazine showed notable systemic toxicity, particularly by inhalation exposure. These studies reported that hydrazine is hepatotoxic, has CNS toxicities (although not described after oral treatment), and is genotoxic as well as carcinogenic (see also section 4.4).

 

 

 

Updated on 19/07/2010 and displayed until 08/09/2010
Reasons for adding or updating:
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   08-Jul-2010
Legal Category:   POM
Black Triangle (CHM):   YES

Free-text change information supplied by the pharmaceutical company

Section 9:

From:

21 January 2004

To:

21 January 2009


Section 10:

From:

22 May 2009

To:

8 July 2010
Updated on 09/06/2009 and displayed until 19/07/2010
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
  • Change to section 6. 3 - Shelf Life
  • Change to section 6. 6 - Instructions for use, handling and disposal
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   22-May-2009
Legal Category:   POM
Black Triangle (CHM):   YES

Free-text change information supplied by the pharmaceutical company

Section 4.8:

  • Flare ups have been removed
  • The following has also changed from (changes in bold):

 

The device: Complications with the device are very common (>1/10), e.g. connector leakage, dislocation of the intestinal tube. Dislocation of the intestinal tube backwards into the stomach leads to reappearance of motor fluctuations (due to erratic gastric emptying of Duodopa into the small intestines). In general, relocation of the tube can be done using a guide-wire to steer the tube into the duodenum under fluoroscopy. Occlusion, kinks, or knots of the intestinal tube lead to high pressure signals from the pump. Occlusions are usually remedied by flushing the tube with tap water; kinking, knotting, or a tube replacement may need readjustment of the tubing. Should complete failure of the intestinal tube or pump occur the patient must be treated with oral levodopa/carbidopa until the problem is solved. The stoma usually heals without complications. However, abdominal pain, infection and leakage of gastric fluid may occur shortly after surgery; it is rarely a problem long-term. Reported complications include wound infection (the most common complication) and peritonitis. Local infections around the stoma are treated conservatively with a disinfectant. Treatment with antibiotics is rarely needed.

To:  

 

The device: Complications with the device are very common (>1/10), e.g. connector leakage, dislocation of the intestinal tube. Dislocation of the intestinal tube backwards into the stomach leads to reappearance of motor fluctuations (due to erratic gastric emptying of Duodopa into the small intestines). In general, relocation of the tube can be done using a guide-wire to steer the tube into the duodenum under fluoroscopy. Occlusion, kinks, or knots of the intestinal tube lead to high pressure signals from the pump. Occlusions are usually remedied by flushing the tube with tap water; kinking, knotting, or a tube displacement may need readjustment of the tubing. Should complete failure of the intestinal tube or pump occur the patient must be treated with oral levodopa/carbidopa until the problem is solved. The stoma usually heals without complications. However, abdominal pain, infection and leakage of gastric fluid may occur shortly after surgery; it is rarely a problem long-term. Reported complications include perforation of adjacent anatomical structures especially during PEG placement and bleeding, wound infection (the most common complication) and peritonitis. Local infections around the stoma are treated conservatively with a disinfectant. Treatment with antibiotics is rarely needed.

Section 6.3 changes from:

15 weeks.

 

Chemical and physical in-use stability has been demonstrated for 16 hours at 40°C.

To:

Unopened: 15 weeks.

Once opened: Use immediately. Discard any unused portion.

 

Chemical and physical in-use stability has been demonstrated for 16 hours at 40°C.

Section 6.6 changes from:

Any unused product or waste material should be disposed of in accordance with local requirements.

Empty/used cassettes should be returned to the pharmacy for destruction.

To:

Cassettes are for single use only.

Do not re-use an opened cassette.

Any unused product or waste material should be disposed of in accordance with local requirements.

Empty/used cassettes should be returned to the pharmacy for destruction.

 

Updated on 17/04/2008 and displayed until 09/06/2009
Reasons for adding or updating:
  • New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC

Active Ingredients/Generics

 
   levodopa
   carbidopa monohydrate